Efficacy of adoptive immunotherapy after mixed hematopoietic stem cell transplantation on acute myeloid leukemia.
- Author:
Cun-Bang WANG
1
;
Hai BAI
;
Rui XI
;
Yao-Zhu PAN
;
Qian ZHANG
;
Jin-Mao ZHOU
;
Tao WU
;
Shu-Fen XU
Author Information
1. Department of Hematology, Lanzhou General Hospital, Gansu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Female;
Hematopoietic Stem Cell Mobilization;
Hematopoietic Stem Cell Transplantation;
Humans;
Immunotherapy, Adoptive;
Leukemia, Myeloid, Acute;
therapy;
Male;
Transplantation, Homologous;
Young Adult
- From:
Journal of Experimental Hematology
2012;20(5):1162-1166
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to investigate the efficacy of treatment with haploidentical donor's lymphocyte infusion(hiDLI) combined with interleukin-2 (IL-2) after transplantation of autologous peripheral blood stem cells mixed with haploidentical allogeneic bone marrow (mix-HSCT) for acute myeloid leukemia (AML). 49 patients diagnosed as AML were enrolled in this study. After preconditioning with TBI plus VEMAC regimen, all patients received mix-HSCT. Autologous peripheral blood hematopoietic stem cells were mobilized with chemotherapy-combined G-CSF, and haploidentical allogeneic bone marrow cells were not mobilized with G-CSF. 33 patients in test group were treated with hiDLI plus IL-2 for 1-8 times after hematopoietic reconstruction, 16 patients in control group received mix-HSCT only. All the patients were followed-up for more than 3 years. The results showed that all the patients obtained hematopoietic reconstruction, and no graft-versus-host disease (GVHD) was found. In two groups, the median time of absolute neutrophil count (ANC) ≥ 0.5×10(9)/L was 14 (12 - 18) and 14 (11 - 16) days, and WBC count ≥ 4.0×10(9)/L was 17 (16 - 22) and 18(17 - 20) days, Plt count ≥ 50×10(8)/L were 25 (24 - 29) and 25 (23 - 26) days. 9 patients in test group formed mixed chimerism (46XX/46XY) and sustained about 3 - 12 months; disease-free survival (DFS) was 63.6%, 3 patients in control group formed mixed chimerism (46XX/46XY), persistent about 3-6 months; DFS was 50.0%. It is concluded that treatment with hiDLI plus IL-2 after mix-HSCT for AML patients may increase DFS efficiently.
